Industry satellite symposium at the 3rd European Lung Cancer Congress in Geneva, Switzerland. This symposium, sponsored by Boehringer Ingelheim, was entitled ‘Signal transduction and molecular diagnostics in NSCLC: recent advances in clinical research and practice’ and has taken place on April 20th.
At this event renowned international cancer experts have taken a deeper look at current and future treatment options in Non-Small Cell Lung Cancer (NSCLC). The first two speakers reviewed current treatment approaches utilizing ErbB Family Blockade and EGFR mutation testing, and the third speaker analyzed the role of angiokinase inhibition in NSCLC.
These topics had been discussed in presentations and a subsequent question and answer sessions including the audience.
We hope you have enjoyed the meeting and look forward to sharing an informative and inspiring session with you!
Chairperson: James Spicer (UK)
Date: Friday 20th April 2012, 18:10 - 19:10
Location: Room C, Geneva Palexpo, ELCC, Geneva
|18:15||Skies are blue: multidisciplinary aspects in EGFR mutation testing
|18:30||Where troubles melt like lemon drops: role of ErbB Family
Blockade in NSCLC
|18:45||Dreams that you dare to dream: role of Angiokinase Inhibition in NSCLC
|19:00||Question session/ discussion|